en
svPress releases
Regulatory press release 2024-12-02
Strong interest in Xspray Pharma AB’s rights issue – preliminary outcome is published
Regulatory press release 2024-11-14
Xspray publishes prospectus relating to the rights issue
Regulatory press release 2024-11-06
Interim Report Third Quarter 2024
Regulatory press release 2024-11-06
Xspray resolves on a rights issue of approximately SEK 135 million and raises a loan of SEK 100 million
Regulatory press release 2024-10-21
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2025
Press release 2024-09-19
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
Regulatory press release 2024-08-07
Interim Report Second Quarter 2024
Regulatory press release 2024-07-26
Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development
Regulatory press release 2024-07-09
Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose
Regulatory press release 2024-05-31